Gene Editing, Gene Sequencing, Gene Therapy and In-Vivo

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). The Swiss pharma group is paying $75 million upfronting cash and equity to get the ball rolling on the collaboration, with another $1.4

Gene Editing

Gene Editing In-Vivo Gene Sequencing Gene

Clinical Research Informer

Precision Bio climbs on near-$1.5bn sickle cell pact with Novartis

Stay Connected